Musculoskeletal Adverse Events Associated with Adjuvant Aromatase Inhibitors

Table 2

Incidence of arthralgia and myalgia in postmenopausal women with early breast cancer as reported from phase III trials of third-generation aromatase inhibitors in the adjuvant setting.

Phase 3 trial	Median followup (months)	Arthralgia (%)	Myalgia (%)
ATAC [1]	68	35.6% ANA versus 29.4% TAM^a; 𝑃<.0001	NR
BIG 1-98 [2]	25.8	20.3% LET versus 12.3% TAM^b; 𝑃<.001	6.4% LET versus 6.1% TAM; P =.61
BIG 1-98 [8]	51	20.0% LET versus 13.5% TAM; 𝑃<.001	7.1% LET versus 6.1% TAM; 𝑃=.19
TEAM [21]	33	17.9% EXE versus 9.2% TAM; 𝑃<.001	NR
IES [3]	55.7	20.8% EXE versus 15.1% TAMb; 𝑃<.0001	25.7% EXE versus 20.3% TAMc; 𝑃<.0001
ABCSG 8/ARNO 95 [22]	28	19% ANA versus 16% TAMd; 𝑃=.0546	NR
ARNO 95 [23]	30.1	11.7% ANA versus 4.9% TAMe	NR
MA.17 [24]	30	25% LET versus 21% PLAb; 𝑃<.001	15% LET versus 12% PLA; 𝑃=.004

ABCSG: austrian breast and colorectal cancer study group; ANA: anastrozole; ARNO: arimidex-nolvadex; ATAC: arimidex tamoxifen alone or in combination; BIG: breast international group; EXE: exemestane; IES: intergroup exemestane study; LET: letrozole; PLA: placebo; TAM: tamoxifen; TEAM: tamoxifen exemestane adjuvant multicenter; NR: not reported.
aGrade not specified.
bAll grades.